Earnings summaries and quarterly performance for Tyra Biosciences.
Executive leadership at Tyra Biosciences.
Board of directors at Tyra Biosciences.
Research analysts covering Tyra Biosciences.
Recent press releases and 8-K filings for TYRA.
Tyra Biosciences Strengthens Leadership with Key Appointments
TYRA
Management Change
Hiring
- Tyra Biosciences has appointed Bhavesh Ashar as Chief Operating Officer, effective immediately. Mr. Ashar previously served as Chief Commercial Officer at SpringWorks Therapeutics, Inc..
- Heather Faulds has been appointed Chief Regulatory Officer, with her appointment effective December 8, 2025. Ms. Faulds brings over 20 years of experience in global regulatory strategies, most recently from Blueprint Medicines.
- These appointments are critical for advancing the company's lead precision medicine candidate, oral dabogratinib, through global Phase 2 studies in skeletal dysplasia and urologic cancers and preparing for potential future pivotal Phase 3 studies.
Dec 1, 2025, 1:00 PM
TYRA Biosciences Provides Update on Dabogratinib Clinical Programs and Financials
TYRA
New Projects/Investments
Guidance Update
- TYRA Biosciences' lead drug, dabogratinib, an oral FGFR3 selective inhibitor, is currently in Phase 2 studies for intermediate risk non-muscle invasive bladder cancer (NMIBC) and achondroplasia, and has recently been cleared to proceed with a Phase 2 study in upper tract urothelial carcinoma.
- The company expects initial 3-month complete response (CR) data for the NMIBC Phase 2 study (from 20-30 patients across 50mg and 60mg cohorts) to be available towards the end of the first half of 2026.
- For the achondroplasia program, six-month annualized height velocity (AHV) data from the sentinel cohorts in the Phase 2 study is anticipated in the second half of 2026. TYRA aims to double the efficacy observed with other agents in achondroplasia.
- TYRA Biosciences is well financed into 2028 with $275 million in the bank.
Nov 19, 2025, 4:00 PM
TYRA Biosciences Provides Update on Dabogratinib Clinical Programs
TYRA
New Projects/Investments
- TYRA Biosciences' lead drug, dabogratinib, an oral FGFR3 selective inhibitor, has been cleared for a Phase II study in upper tract urothelial carcinoma and is currently in two other Phase II studies for intermediate risk NMIBC and achondroplasia.
- For intermediate risk NMIBC, data on 3-month complete response (CR) from the first 20-30 patients is anticipated by the end of the first half of 2026.
- In achondroplasia, six-month annualized height velocity (AHV) data from all sentinel cohorts is expected in the second half of 2026.
- The company is well-financed into 2028 with $275 million in the bank and plans to advance dabogratinib into Phase III for multiple indications based on upcoming data.
Nov 19, 2025, 4:00 PM
TYRA Provides Updates on Dabogratinib Clinical Programs and Financial Runway
TYRA
New Projects/Investments
Guidance Update
- TYRA's lead drug, dabogratinib, an FGFR3 selective inhibitor, is currently in Phase 2 studies for intermediate risk non-muscle invasive bladder cancer (NMIBC), achondroplasia, and recently received clearance for a Phase 2 study in upper tract urothelial carcinoma (UTUC).
- The company anticipates key data readouts in 2026, with NMIBC data (20-30 patients, 3-month CR) expected by the end of the first half and achondroplasia data (six-month AHV) in the second half.
- TYRA aims to demonstrate a superior safety profile for dabogratinib in NMIBC by mitigating off-target toxicities seen with pan-FGFR inhibitors, and to double the annualized height velocity benefit in achondroplasia compared to current competitors.
- TYRA is well financed into 2028 with $275 million in the bank.
Nov 19, 2025, 4:00 PM
TREOS Bio Publishes Positive Phase 1b Clinical Trial Results for PolyPEPI1018
TYRA
Product Launch
New Projects/Investments
- TREOS Bio announced the publication of positive results from its OBERTO-201 Phase 1b study in Journal of Clinical Oncology - Oncology Advances, evaluating PolyPEPI1018 plus TAS-102 for refractory microsatellite-stable metastatic colorectal cancer (MSS mCRC).
- The combination therapy demonstrated general tolerability with PolyPEPI1018-related adverse events limited to Grade 1–2 local injection-site reactions and no immune-related systemic toxicities observed.
- Key efficacy outcomes included a 53.3% disease control rate (DCR), median progression-free survival (mPFS) of 4.0 months, and median overall survival (mOS) of 8.7 months, showing promising improvements over historical TAS-102 monotherapy.
- The study highlighted the potential for precision-immunotherapy, with patients predicted by HLA genotype to have broader T-cell responses achieving longer survival (mOS 10.3 vs 4.6 months).
- These findings, combined with results from the OBERTO-301 trial, have informed the design of TREOS’ Phase II clinical programme for late-stage MSS mCRC.
Nov 6, 2025, 12:00 PM
Tyra Biosciences Reports Q3 2025 Financial Results and Clinical Progress
TYRA
Earnings
New Projects/Investments
- Tyra Biosciences reported a net loss of $29.9 million for the third quarter ended September 30, 2025, with Research and Development (R&D) expenses of $25.5 million and General and Administrative (G&A) expenses of $7.5 million.
- As of September 30, 2025, the company maintained a strong financial position with $274.9 million in cash, cash equivalents, and marketable securities, providing a projected financial runway through at least 2027.
- The company advanced its lead candidate, dabogratinib, by dosing the first patients in Phase 2 studies BEACH301 (pediatric achondroplasia) and SURF302 (IR NMIBC), and expanded its development into low-grade upper tract urothelial carcinoma (LG-UTUC) with an IND cleared for the SURF303 study.
- Upcoming clinical milestones for dabogratinib include initial results from the BEACH301 safety sentinel cohort in 2H 2026, initial three-month complete response data from SURF302 in 1H 2026, and the initiation of the SURF303 Phase 2 study in 2026.
Nov 5, 2025, 9:08 PM
Tyra Biosciences Reports Q3 2025 Financial Results and Clinical Progress
TYRA
Earnings
New Projects/Investments
Guidance Update
- Tyra Biosciences reported cash, cash equivalents, and marketable securities of $274.9 million as of September 30, 2025, which is expected to provide a financial runway through at least 2027.
- For the third quarter ended September 30, 2025, the company reported a net loss of $29.9 million, compared to $24.0 million for the same period in 2024.
- Research and Development (R&D) expenses increased to $25.5 million for Q3 2025, up from $22.7 million in Q3 2024, primarily due to start-up and enrollment activities for BEACH301, SURF302, and SURF431.
- The company expanded the development of dabogratinib into low-grade upper tract urothelial carcinoma (LG-UTUC) with an Investigational New Drug application (IND) cleared by the FDA, and expects interim results from the BEACH301 and SURF302 Phase 2 studies in 2026 and 1H 2026, respectively.
Nov 5, 2025, 9:05 PM
TREOS Bio Initiates Pivotal Phase II Clinical Trial and Secures Bridge Financing
TYRA
New Projects/Investments
- TREOS Bio has initiated OBERTO-202, a potentially registration-enabling Phase II clinical trial, through collaboration agreements with Charité – Universitätsmedizin Berlin and Junshi Biosciences.
- The trial will evaluate PolyPEPI1018, TREOS Bio's lead immunotherapy, combined with toripalimab and standard of care, in approximately 140 patients with relapsed/refractory microsatellite stable (MSS) metastatic colorectal cancer (CRC).
- MSS CRC represents approximately 85% of all colorectal cancer cases, affecting an estimated 130,000 new patients annually in the US, and is a population where current immunotherapies have shown limited efficacy.
- The company also completed a $2.1 million bridge financing from existing investors, increasing total financing raised to date to $47 million.
Aug 27, 2025, 11:00 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more